NBF2, an Algal Fiber-Rich Formula, Reverses Diabetic Dyslipidemia and Hyperglycemia In Vivo.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Hyperglycemia*/drug therapy ; Dyslipidemias*/drug therapy ; Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/metabolism; Animals ; Rats ; Male ; Blood Glucose/metabolism ; Blood Glucose/drug effects ; Dietary Fiber/pharmacology ; Rats, Inbred OLETF ; Insulin Resistance

Ulva prolifera , known as Aonori in Japan, is an edible alga species that is mass-cultivated in Japan. Supplementation with Aonori-derived biomaterials has been reported to enhance metabolic health in previous studies. This was an experimental study that evaluated the metabolic health effects of NBF2, a formula made of algal and junos Tanaka citrus -derived biomaterials, on obesity and type 2 diabetes (T2DM). We used 18 obese and hyperglycemic Otsuka Long-Evans Tokushima Fatty (OLETF) rats that were assigned randomly to three groups of six animals: a high-dose NBF2 drink (20 mg/kg) group, a low-dose (10 mg/kg) NBF2 drink group and the control group that received 2 mL of tap water daily for a total of six weeks. We also used eight LETO rats as the normal control group. In addition to the glucose tolerance test (OGTT), ELISA and real-time PCR assays were performed. High-dose and lowdose NBF2 improved insulin sensitivity, as well as glycemic and lipid profiles, as compared with control rats. The OGTT showed that both NBF2 groups and LETO rats had normalized glycemia by the 90-min time-point. NBF2 up-regulated PPARα/γ-mRNA and Sirt2-mRNA gene expressions in BAT and improved the blood pressure profile. These findings suggest that the NBF2 formula, which activates PPAR-α/γ mRNA and Sirt2-mRNA, may reverse dyslipidemia and hyperglycemia in T2DM.

Mar Drugs. 2017 Feb 08;15(2):. (PMID: 28208744)
Cell Mol Life Sci. 2014 May;71(10):1917-25. (PMID: 24322911)
Cell Rep. 2020 Mar 3;30(9):3079-3091.e5. (PMID: 32130908)
Int J Mol Sci. 2018 Jul 05;19(7):. (PMID: 29976894)
Hepatology. 2021 Aug;74(2):723-740. (PMID: 33636024)
Lancet. 2022 Jan 22;399(10322):394-405. (PMID: 34600604)
J Clin Invest. 2006 Jul;116(7):1784-92. (PMID: 16823476)
Mol Metab. 2020 Jun;36:100964. (PMID: 32248079)
Front Endocrinol (Lausanne). 2022 Oct 13;13:1004044. (PMID: 36313764)
Nat Med. 2002 Nov;8(11):1288-95. (PMID: 12368907)
Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124. (PMID: 33298420)
Nutr Metab (Lond). 2010 Aug 24;7:67. (PMID: 20735814)
J Epidemiol. 2013;23(3):187-94. (PMID: 23545576)
Nature. 2000 May 25;405(6785):421-4. (PMID: 10839530)
Sci Rep. 2019 Feb 7;9(1):1656. (PMID: 30733541)
Life Sci. 2021 Nov 15;285:119997. (PMID: 34597608)
J Physiol Pharmacol. 2006 Nov;57 Suppl 6:103-13. (PMID: 17228091)
Drug Des Devel Ther. 2015 Jan 17;9:525-35. (PMID: 25632221)
Biomedicines. 2022 Oct 14;10(10):. (PMID: 36289836)
Sci Rep. 2019 Dec 12;9(1):19017. (PMID: 31831868)
Nat Commun. 2018 Jan 2;9(1):30. (PMID: 29296001)
J Food Sci. 2010 Apr;75(3):H87-92. (PMID: 20492298)
Cardiovasc Diabetol. 2018 Jul 7;17(1):98. (PMID: 29981570)
Endocrinology. 2009 Feb;150(2):625-33. (PMID: 18927219)

Keywords: algal formula; dyslipidemia; hyperglycemia; peroxisome proliferation-activated receptor; sirtuin; type 2 diabetes

0 (Blood Glucose)
0 (Dietary Fiber)

Date Created: 20241016 Date Completed: 20241016 Latest Revision: 20241019

20241019

PMC11476984

10.3390/ijms251910828

39409158